On February 21, 2024, Acadia Pharmaceuticals Inc. discovered that their information systems had been compromised, leading to unauthorized data exfiltration. The breach was identified promptly, and the company took immediate steps to contain the situation. By April 10, 2024, it was confirmed that personal information of some individuals was indeed affected. The breach involved sophisticated cyber-attack techniques, but specific details about the perpetrators or the exact method of attack have not been disclosed publicly.
The following types of consumer information were exposed during the breach:
Immediately upon detection of the breach, Acadia Pharmaceuticals Inc. engaged with law enforcement, cybersecurity experts, and outside legal counsel to investigate and mitigate the effects of the breach. The company has since been working diligently to reinforce their security systems and protocols to prevent future incidents. Additionally, they are offering affected individuals free access to credit monitoring and identity restoration services through Experian IdentityWorksSM for 24 months.
If you believe your information may have been compromised in this breach, it is crucial to remain vigilant and proactive in monitoring your personal information. Here are some steps you can take:
For more detailed information regarding the breach, you can visit the disclosure notices on the Texas Attorney General's website and the California Attorney General's website.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company known for developing and commercializing medicines aimed at central nervous system disorders. They have pioneered treatments for conditions such as Parkinson’s disease psychosis and Rett syndrome.